IngredientsMelaleuca alternifolia (Maiden & Betche) Cheel is an Australian native plant belonging to the family Myrtaceae, and is the primary source of the volatile essential oil commonly known as tea tree oil (TTO). The species was first formally described in 1905 by Joseph Maiden and Ernst Betche, given the name Melaleuca linariifolia var. alternifolia in the Proceedings of the Linnean Society of New South Wales, before Edwin Cheel raised the variety to species status as Melaleuca alternifolia in 1925. The specific epithet alternifolia is derived from the Latin alternus meaning "alternate" and folium meaning "leaf," referring to the leaf arrangement.
Tea tree oil, also known as melaleuca oil, is an essential oil with a fresh, camphoraceous odour and a colour ranging from pale yellow to nearly colourless and clear; it is derived from the leaves of the tea tree, Melaleuca alternifolia, native to southeast Queensland and the northeast coast of New South Wales, Australia. The common name "tea tree" is historically associated with Captain James Cook's voyages to Australia in the 1770s, during which sailors brewed a spiced tea from the leaves.
Melaleuca alternifolia is endemic to Australia, found from the Grafton district in New South Wales as far inland as Stroud and in coastal districts north to Maryborough in Queensland; it grows along streams and in swampy places, thriving in a wide range of soils and climates, though it prefers moist, well-drained soils and full sun. It is characterised as a small tree.
Tea tree oil is derived from the leaves of the plant by steam distillation. According to ISO criteria laid down in ISO 4730, TTO may also be obtained from Melaleuca linariifolia Smith and Melaleuca dissitiflora F. Mueller, although commercial TTO is produced almost exclusively from M. alternifolia.
In 2021, Australia accounted for 81% of the global production for steam-distilled, ISO 4730:2017-compliant tea tree oil. Tea tree oil is used in healthcare/household, cosmetic, pharmaceutical, and aromatherapy products, and is increasingly formulated into shampoos, soaps, liquid body washes, mouthwashes, and over-the-counter treatments for cold sores, acne, burns, bites, lice, and fungal nail infections.
Commercial preparations of TTO include:
The tea tree essential oil can be classified into three major chemotypes: terpinen-4-ol, terpinolene, and 1,8-cineole; the terpinen-4-ol chemotype is dominant and also medicinally more interesting.
The medicinal significance of Melaleuca alternifolia is deeply rooted in Aboriginal traditions, where it served as a frontline remedy long before Western science recognized its potential; for the Bundjalung people of eastern Australia, tea tree leaves were not simply herbal aids but essential tools in everyday healthcare.
First Nations Australians have a long oral history of using the tea tree plant for medicinal purposes, which they still practice today; the earliest written record of its use was that of the Bundjalung people of northern New South Wales, who used it to treat wounds, burns, insect bites, and upper respiratory infections.
The Bundjalung people traditionally lived in the area of north-eastern New South Wales where Melaleuca alternifolia is endemic, and they treated skin infections by crushing the leaves over skin infections and then covering the area with a warm mudpack. Indigenous Australians of eastern inland areas also used tea trees by inhaling the oils from the crushed leaves to treat coughs and colds. For thousands of years, Aborigines used the leaves for many medicinal purposes, including chewing the young leaves to alleviate headache, and used the crushed leaves as an antiseptic and antifungal by making a mudpack.
The medicinal properties of Melaleuca alternifolia were unknown outside the Australian Aboriginal people until the early 1920s, when Australian chemist Dr. Arthur Penfold researched its antiseptic properties. Arthur Penfold described the medicinal value of tea tree essential oil in 1925, although the first official Australian report of its use in Western medicine was a 1930 article published in the Medical Journal of Australia, where it was described as having "impressive wound healing and antiseptic qualities."
Commercial use of tea tree oil began in the 1920s, pioneered by the entrepreneur Arthur Penfold. During World War II, TTO was reportedly included in first-aid kits for Australian soldiers working in tropical climates, though interest waned with the wide availability of antibiotics. Interest resurged in the 1970s and 1980s as research into natural antimicrobials intensified.
According to the European Medicines Agency (EMA) monograph, tea tree oil has a well-established use as a traditional herbal medicinal product for: (1) the treatment of small superficial wounds and insect bites; (2) the treatment of small boils (furuncles and mild acne); (3) relief of itching and irritation in cases of mild athlete's foot; and (4) symptomatic treatment of minor inflammation of the oral mucosa, based upon its long-standing use for these indications.
Tea tree oil is a complex mixture of over 100 volatile compounds, predominantly monoterpenes, sesquiterpenes, and their oxygenated derivatives. TTO contains approximately 100 terpenes and their related alcohols. The monoterpenes terpinen-4-ol, α-terpinene, 1,8-cineole, p-cymene, α-terpineol, α-pinene, terpinolene, limonene, and sabinene account for 80–90% of the oil.
TTO composition is standardised by the international norm ISO 4730:2017 ("Oil of Melaleuca, terpinen-4-ol type"), which defines acceptable ranges for key components to ensure quality and consistency in commercial products. International Standard ISO 4730 requires ≥30% terpinen-4-ol (often 35–40% in optimised cultivars) and ≤15% 1,8-cineole, alongside regulated levels of twelve other constituents.
The ISO-permitted concentration ranges for major constituents are as follows:
Across analytical studies of commercial TTOs by GC-MS, samples were characterised by high terpinen-4-ol content (37.66–44.28%), followed by γ-terpinene (16.42–20.75%), α-terpinene (3.47–12.62%), α-terpineol (3.11–4.66%), terpinolene (2.75–4.19%), p-cymene (1.66–11.47%), α-pinene (1.29–2.66%), aromadendrene (1.20–1.90%), 1,8-cineole (1.17–4.79%), ledene (0.47–1.69%), and limonene (0.30–1.63%).
The percentages of compounds in TTO can vary slightly according to the region of plant harvest, the distillation technique, or the part of the plant used for oil extraction. The oil's composition also changes if it is exposed to air and oxidises.
The International Organization for Standardization defines terpinen-4-ol as the primary active constituent, comprising 35–48% of tea tree oil. Terpinen-4-ol is a naturally occurring monoterpene alcohol with good antimicrobial properties; it is effective against methicillin-resistant S. aureus (MRSA) and fluconazole-resistant C. albicans. While terpinen-4-ol is considered the most active ingredient, experiments using terpinen-4-ol alone have shown it is not nearly as effective as the complete oil.
The essential oil of Melaleuca alternifolia has broad-spectrum antimicrobial activity; the mechanisms of action of TTO and three of its components — 1,8-cineole, terpinen-4-ol, and α-terpineol — against Staphylococcus aureus ATCC 9144 have been investigated, with treatment at their minimum inhibitory concentrations (MICs), particularly terpinen-4-ol and α-terpineol, reducing the viability of S. aureus.
The primary premise is that TTO and/or its components act on microbial membranes; the loss of 260-nm-absorbing material, increased susceptibility to NaCl, formation of mesosomes, and loss of cytoplasmic material all suggest that the cytoplasmic membrane is compromised by treatment with TTO and its components. Terpinen-4-ol induces membrane disruption, compromising the integrity and physiology of microbial cells.
The increased antimicrobial activity of terpinen-4-ol depends on the simultaneous presence of both hydrophilic and hydrophobic characteristics sufficient to allow diffusion through the water present around the bacterial cytoplasmic membrane and through the phospholipid layer of the cytoplasmic membrane.
Loss of 260-nm-absorbing material occurred after treatment with concentrations equivalent to the MIC, particularly after treatment with 1,8-cineole and α-terpineol; organisms treated with TTO or its components at the MIC or two times the MIC also showed a significant loss of tolerance to NaCl.
TTO, terpinen-4-ol, and alpha-terpineol can suppress the production of inflammatory mediators in LPS-stimulated human macrophages; this inhibition is mediated by interfering with the NF-κB, p38, or ERK MAPK pathways. In experimental settings using a human monocytic cell line differentiated into macrophages, LPS-induced production of all cytokines was reduced significantly by TTO and its components, including IL-1β, IL-6, and IL-10.
Terpinen-4-ol can significantly inhibit the activation of NF-κB, thereby reducing the inflammatory response; in LPS-stimulated intestinal epithelial cells, IL-6 and TNF-α were upregulated but this phenomenon disappeared with terpinen-4-ol pretreatment, indicating significant anti-inflammatory activity.
Chemotyped oils dominated by terpinen-4-ol — supported by γ-/α-terpinene, 1,8-cineole, and selected sesquiterpenes — exert coordinated actions that destabilise microbial membranes, impair energy metabolism, modulate redox and inflammatory pathways (PPAR-γ, Nrf2–ARE), and, in cancer models, trigger mitochondrial apoptosis and autophagy.
TTO also prevents NF-κB and inhibitor of NF-κB (IκB) phosphorylation, which is important for NF-κB activation and the expression of inflammatory cytokines including TNF-α and IL-6.
The anti-parasitic effects of TTO's major constituents are mainly due to their anti-histamine and anti-acetylcholinesterase activities as well as their ability to modulate host inflammatory responses.
The complex chemical composition of tea tree oil makes it difficult for bacteria to develop resistance, whereas traditional antibiotics possess simpler structures, allowing the easier development of immunity.
Tea tree oil is well-known for its medicinal properties; however, the evidence for most applications is limited. A 2023 systematic review of randomised controlled trials (RCTs) identified 46 eligible articles spanning the medical fields of dentistry (n=18), dermatology (n=9), infectious disease (n=9), ophthalmology (n=6), podiatry (n=3), and other (n=1). Side effects were reported in 60% of included studies and were generally minor, except where TTO was applied topically in concentrations ≥25%; overall, the quality of research was characterised as poor to modest, and higher-quality trials with larger samples and better reporting are required to substantiate potential therapeutic applications.
In medicine, TTO is used against acne and has been reported to improve wound healing. A key RCT in this area used a 5% TTO gel formulation. This randomised, double-blind clinical trial was performed in 60 patients with mild to moderate acne vulgaris, randomly divided into two groups treated with tea tree oil gel (n=30) or placebo (n=30), followed every 15 days for a period of 45 days, with response evaluated by total acne lesion count (TLC) and the acne severity index (ASI). There was a significant difference between the tea tree oil gel and placebo in improvement of both the TLC and the ASI.
There is limited evidence showing that TTO may help treat certain health conditions, and the NCCIH advises that research into the effects of topical tea tree oil on people is limited; some limited research suggests that tea tree oil may be beneficial for people with acne. Evidence from this area is rated as preliminary — small sample sizes and short follow-up periods are consistent limitations.
A 2023 systematic review noted that in studies from 1992 and 2002, clinical signs and symptoms of athlete's foot improved in a greater proportion of study participants using tea tree oil compared to placebo; however, the authors highlighted that some participants experienced adverse effects, such as dermatitis, after using the tea tree oil. The EMA's recognition of TTO as a traditional herbal medicinal product includes the relief of itching and irritation in cases of mild athlete's foot, based on long-standing use. The overall evidence for tinea pedis is preliminary and confined to small trials.
In a controlled study of patients with subungual onychomycosis, participants received either 100% TTO or 1% clotrimazole twice daily for 6 months; at the end of the trial, 18% of TTO-treated patients and 11% of control patients had negative cultures, with full or partial resolution of symptoms experienced by 60% and 61% of patients respectively, though these differences were not statistically significant. In a subsequent trial (Jadad score 4; n=60), patients received either 2% butenafine hydrochloride combined with 5% TTO cream or a TTO-only cream for toenail onychomycosis, applied thrice daily for 8 weeks. Overall cure rates (resolution of clinical symptoms, negative culture, and progressive growth of normal nail) at 9 months were 80% for the combined cream and 0% for controls.
Five clinical studies on TTO for onychomycosis have been identified in the systematic review literature; results are mixed, with no strong evidence for TTO monotherapy and some positive signals for combination preparations. Evidence is rated as weak to preliminary.
Satchell et al. (2002) compared daily hair washing with a 5% tea tree oil shampoo or a placebo shampoo for treatment of dandruff in 126 subjects aged 16 and older; reduction in both the area of scalp involved and severity of dandruff was significantly greater in subjects washing with the tea tree oil shampoo compared with placebo. This is one of the more frequently cited positive RCTs for TTO, but replication in larger trials is needed to confirm findings.
Washing with 5% tea tree oil has been shown to be effective in removing MRSA on the skin. TTO 10% cream, 5% body wash, chlorhexidine 4%, and silver sulfadiazine 1% were used for MRSA decolonisation of superficial skin sites and skin lesions; this study indicated that the TTO formulations were more effective than the drug control groups. In a randomised controlled trial with 391 patients, a 5% TTO body wash was able to prevent MRSA colonisation compared to a standard non-medicated body wash.
In one systematic review, a non-significant but higher proportion of MRSA was cleared in the essential oil group (69%) compared to routine care (45%); essential oils significantly lowered the level of new MRSA emergence (9% vs. 53% in routine care). Reviewers concluded that essential oils could be considered as an alternative treatment for MRSA decolonisation, though low quality and heterogeneity among studies calls for further research. TTO shows promise for countering methicillin-resistant Staphylococcus aureus (MRSA), known as the hospital "super bug." The evidence is rated as promising but preliminary, given study heterogeneity and small sample sizes.
Results from the 2023 systematic review indicate that oral mouthwashes with 0.2–0.5% tea tree oil have been investigated across 18 dentistry RCTs — the largest single category in the review. The EMA's traditional-use classification also recognises symptomatic treatment of minor inflammation of the oral mucosa. However, the majority of oral health trials remain small and of modest quality. Research areas include gingivitis, periodontitis, and oral candidiasis, though no strong definitive conclusions can be drawn from the current evidence base alone.
There are a few randomised controlled studies and open-label trial studies published evaluating therapeutic options for human demodicosis; recommendations for specific treatment have not consistently accounted for product availability or regulatory approval. More evidence on efficacy of tea tree oil-based eyelid wipes for Demodex mite control is needed. There is little evidence for the effectiveness of tea tree oil in treating mite-infected crusting of eyelids.
An older 2011 study compared several treatments for contact dermatitis, including tea tree oil, zinc oxide, and clobetasone butyrate; the results suggested that tea tree oil was more effective in suppressing allergic contact dermatitis than other treatments, though it did not affect irritant contact dermatitis. Evidence is limited to a single small trial and requires independent replication.
Australian tea tree oil and its monoterpene constituents such as terpinen-4-ol, 1,8-cineole, limonene, p-cymene, and α-terpinene have been shown to be effective in controlling a wide range of parasitic infections; the anti-parasitic effects are mainly due to anti-histamine and anti-acetylcholinesterase activities as well as the ability to modulate host inflammatory responses. Across pathogens, TTO displays antibacterial, antifungal, antiviral, and antiparasitic activity, including effects on drug-resistant biofilms and ectoparasites such as Demodex, scabies, and head lice. The bulk of this evidence, however, remains preclinical or from small pilot studies.
The following dosages appear specifically in the cited clinical and pharmacological literature. These are reported as observed in studies, not as recommendations:
Tea tree oil is highly toxic when ingested orally; it may cause drowsiness, confusion, hallucinations, coma, unsteadiness, weakness, vomiting, diarrhoea, nausea, blood-cell abnormalities, and severe rashes; it should be kept away from pets and children. Taking it orally can cause serious symptoms such as confusion, unsteadiness, inability to walk, and coma. In one reported case, a 4-year-old boy who ingested a small quantity of TTO became ataxic and progressed to unresponsiveness, but recovered within 24 hours of hospital admission. Regarding systemic toxicity after oral intake, there is insufficient toxicological data on tea tree oil poisoning after ingestion in humans, but there have been several case reports.
Most people can use topical products containing tea tree oil without problems, but some people may develop redness or irritation of the skin. Application of TTO to the skin can cause an allergic reaction in some people, the potential for which increases as the oil ages and its chemical composition changes; adverse effects include skin irritation, allergic contact dermatitis, systemic contact dermatitis, linear immunoglobulin A disease, erythema multiforme-like reactions, and systemic hypersensitivity reactions.
Contact dermatitis due to tea tree oil may be caused by the formation of monoterpene oxidation products such as peroxides, epoxides, and endoperoxides due to exposure of the oil to heat, light, or oxygen; this is supported by the correlation between the peroxide number and allergic skin reactions from other essential oils. The occurrence of dermatitis is more common in persons prone to allergic reactions, such as those who already suffer from a skin disease.
The most frequent sensitizers in TTO appear to be ascaridole, terpinolene, alpha-terpinene trihydroxymenthane, alpha-phellandrene, and limonene. Allergic contact dermatitis with an extensive erythema multiforme-like reaction has been observed, as well as linear IgA disease precipitated by contact dermatitis to TTO.
Side effects in clinical trials were generally minor, except where tea tree oil was applied topically in concentrations ≥25%. At low concentrations, terpinen-4-ol demonstrates non-toxicity toward fibroblasts and epithelial cells, making it suitable for topical use with minimal adverse effects.
One small case report found that applying lavender oil and tea tree oil might have led to swelling of breast tissue (gynecomastia) in a young boy; researchers noted they could not determine whether lavender oil or tea tree oil was the cause. This remains an isolated case report and has not been confirmed in controlled studies.
The oil's composition changes if it is exposed to air and oxidises. Oxidised TTO has a higher risk of inducing contact sensitisation due to the formation of degradation products. Proper storage in sealed, dark glass containers away from heat and light is critical to maintain safety and efficacy.
The physical and chemical properties of commercial TTO are regulated by an international standard. Many herbal products intended for oral use are marketed as dietary supplements; the regulatory paths for making and distributing dietary supplements differ from those for drugs, and unlike drugs, dietary supplements are not approved by the U.S. FDA before they are sold to the public. The EMA monograph classifies TTO as a traditional herbal medicinal product for topical indications based upon its long-standing use.
Health conditions that Melaleuca alternifolia may help support.
Tea tree oil from Melaleuca alternifolia has traditional use in Australian Aboriginal medicine for skin infections including abscesses, and carries substantial in vitro and some clinical evidence for broad-spectrum antimicrobial activity. Its primary bioactive terpinen-4-ol is bactericidal against Staphylococcus aureus. A 2023 systematic review of RCTs confirmed antimicrobial and anti-inflammatory properties, though abscess-specific RCT data are limited.
Multiple randomized controlled trials and a 2025 systematic review with meta-analysis support modest efficacy of topical tea tree oil (TTO) for acne vulgaris. A landmark 1990 single-blind RCT (n=124) found 5% TTO gel comparable to 5% benzoyl peroxide in reducing inflamed lesions, with significantly fewer side effects. A 2025 PROSPERO-registered meta-analysis confirmed a modest reduction in acne severity with generally acceptable tolerability, though larger standardized trials are still needed.
Melaleuca alternifolia (tea tree oil) has been evaluated in multiple RCTs for tinea pedis. At 25–50% concentrations applied twice daily for 4 weeks, it produced marked clinical improvement in 68–72% of patients versus 39% for placebo, with 64% mycological cure versus 31% placebo. At 10% concentration it reduced symptoms as effectively as tolnaftate but did not achieve superior mycological cure. Its antifungal activity is attributed to terpinen-4-ol.
Melaleuca alternifolia (tea tree) essential oil inhibits VSC-producing bacteria associated with halitosis including Solobacterium moorei, Porphyromonas gingivalis, and Porphyromonas endodontalis. In vitro studies confirm hydrogen sulfide production is reduced. A clinical study in ICU patients using a TTO-containing mouthwash showed significant reductions in oral malodor and VSC levels. Research from the University of Basel's Institute of Preventive Dentistry substantiated these antimicrobial effects.
Tea tree oil from Melaleuca alternifolia has documented antimicrobial and anti-inflammatory properties supporting its topical use for insect bites and stings. Indigenous Australians traditionally used tea tree leaves for skin injuries including bites. A 2022 PMC systematic review documented its antiparasitic activity against ectoparasites including biting insects (lice, fleas, mites, bed bugs).
Tea tree oil (Melaleuca alternifolia) contains terpinen-4-ol and other antimicrobial compounds that are effective against body odor-causing bacteria including Staphylococcus epidermidis and Corynebacterium species. Multiple laboratory and clinical studies support its broad-spectrum antimicrobial activity. It is widely incorporated into commercial natural deodorant formulations and used topically in Australia for nearly 100 years for antiseptic purposes.
Melaleuca alternifolia (tea tree) oil has documented antifungal activity against azole-susceptible and azole-resistant Candida species in vitro and in animal models of vaginal candidiasis. Its constituent terpinen-4-ol is the primary antifungal agent, acting via membrane disruption. In vivo studies confirm it accelerates Candida clearance from vaginal tissue in rat models.
Melaleuca alternifolia essential oil (tea tree oil) has documented in vitro antiherpetic activity against HSV-1 and HSV-2 via direct virucidal action before cell adsorption. Small clinical observations support reduction in cold sore healing time. It is included within the scope of herbal interventions reviewed in the 2025 systematic review of herbal medicine for herpes labialis.
A randomized, single-blind, parallel-group trial (n=126) found that a 5% tea tree oil shampoo produced a 41% improvement in dandruff severity scores vs. 11% for placebo (p<0.001). Tea tree oil exerts antifungal activity against Pityrosporum ovale (Malassezia), the primary yeast implicated in dandruff. It is recognized as an antimicrobial natural product in pharmaceutical anti-dandruff formulations.
Melaleuca alternifolia (tea tree) oil has clinical evidence for contact dermatitis, particularly nickel-induced contact dermatitis, and antimicrobial/anti-inflammatory effects relevant to seborrheic and atopic dermatitis. It is listed in evidence-based herbal dermatology reviews for treatment of seborrheic dermatitis.
Tea tree oil from Melaleuca alternifolia has demonstrated in vitro antifungal activity against dermatophytes (Trichophyton rubrum, T. mentagrophytes, T. tonsurans), Candida albicans, and Malassezia furfur. Clinical trials show it reduces symptoms of tinea pedis, though it does not always achieve mycological cure equivalent to conventional antifungals. Its main active antifungal component is terpinen-4-ol, which disrupts fungal membrane integrity.
Multiple RCTs support the use of 5% TTO gel, applied subgingivally as an adjunct to scaling and root planing (SRP), for improving clinical periodontal outcomes including pocket depth, attachment level, and inflammatory biomarkers. A 2023 systematic review of 18 dental RCTs found that 5% TTO gels aid treatment of periodontitis as adjunctive therapy, and 0.2–0.5% TTO mouthwashes may limit dental plaque accumulation.
Clinical evidence exists specifically for TTO in treating onychomycosis (fungal nail infection), which is the primary nail-related application. A double-blind RCT (n=117) found 100% TTO comparable to 1% clotrimazole, with ~60% partial or full resolution. TTO acts as an antifungal via terpinen-4-ol disruption of fungal cell membranes, with in vitro activity confirmed against major dermatophytes.
Controlled clinical studies show that 0.2% TTO mouthwash reduces mutans streptococci counts and total oral bacteria, with effects maintained for 2 weeks post-treatment. In vitro data confirms susceptibility of 161 oral bacterial isolates across 15 genera to TTO. A 2025 RCT found 0.2% TTO mouthwash provided antiplaque benefits comparable to chlorhexidine with fewer side effects.
Tea tree oil from Melaleuca alternifolia has been documented in peer-reviewed case reports and a small randomized trial to resolve common warts (verruca vulgaris). A randomized controlled trial found it non-inferior to salicylic acid-lactic acid solution for common warts over 6 weeks. Its major component terpinen-4-ol has documented antiviral and antiseptic properties.
The Bundjalung Aboriginal people of northern New South Wales traditionally applied crushed Melaleuca alternifolia leaves as poultices to treat burns and wounds. The EMA monograph recognizes TTO as a traditional herbal medicinal product for small superficial wounds. Two small clinical trials have examined TTO's effects on blood flow and hemoglobin oxygenation in burn healing, but the evidence base is insufficient for clinical conclusions.
Indigenous Australians—specifically the Bundjalung people of New South Wales—have documented traditional use of inhaled crushed M. alternifolia leaves and infusions for colds, coughs, and upper respiratory infections. No RCTs specifically testing TTO for cold or flu outcomes have been published.
Melaleuca alternifolia (tea tree oil) is recommended by podiatrists and traditional practitioners as an antibacterial and antifungal adjunct for corns, added to foot soaks or applied diluted directly to corn sites to prevent secondary infection and support skin softening. It is incorporated into commercially available corn removal formulations alongside salicylic acid.
The Bundjalung Aboriginal people of New South Wales have well-documented traditional use of M. alternifolia leaf infusions and brewed teas for sore throats. No human RCTs have been published testing TTO specifically for sore throat treatment.
Evidence for TTO in vaginal health is limited to a single published case report of successful self-treatment of bacterial vaginosis with TTO pessaries, and an animal model (rat) supporting use for vaginal candidiasis. No controlled human clinical trials have been published.
Documented Aboriginal traditional use for wound care is the oldest recorded application of M. alternifolia. The EMA monograph formally recognizes TTO as a traditional herbal medicinal product for small superficial wounds. Small human studies exist (MRSA-infected wounds, chronic wound reviews), but robust RCT evidence for wound healing is lacking.
Body systems that Melaleuca alternifolia may help support.
Go back